There exists many types and subtypes of breast cancer, meaning every patient is different and thus requires an individualised treatment approach. The complex nature of these tumours means progress in developing new treatments has been slow. Chemotherapy remains the standard of care for this type of disease.

Despite remarkable progress in this setting to date, some patients will see their disease return in the long-term, which is why there is a critical need to continue to optimise early breast cancer care and to do more to prevent the disease evolving to an advanced, incurable stage. By combining pharmaceutical science, strong diagnostic, digital and genomic capabilities, we are able to innovate and develop treatment options tailored to each individual’s needs. Our advanced diagnostic solutions, and most notably the use of biomarker testing, bring us closer to fulfilling our long-term ambition of offering patients personalised treatment approaches. It’s been an immense challenge, but ongoing research efforts are finally bearing fruit for this challenging disease.